Related Experiment Video
Updated: Jul 19, 2026
09:03
Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
Published on: June 30, 2023
Angiogenesis therapies for cardiovascular disease
Dawn M Pedrotty1, Laura E Niklason
1Department of Biomedical Engineering, and 2Department of Anesthesiology, Duke University, Durham, North Carolina 27708, USA.
Current Opinion in Anaesthesiology
|October 6, 2006
Summary
This review summarizes proangiogenic therapies, including protein and gene therapy clinical trials. It analyzes challenges and outcomes to guide future angiogenesis research and development.
Area of Science:
- Biomedical research
- Cardiovascular science
- Regenerative medicine
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tissue repair and development.
- Proangiogenic therapies aim to stimulate this process for therapeutic benefit.
- Previous clinical trials have shown variable success, necessitating further investigation.
Purpose of the Study:
- To review and analyze findings from clinical trials using protein and gene therapies for proangiogenesis.
- To identify and interpret the challenges and pitfalls encountered in these trials.
- To discuss the implications of current results for the future of angiogenesis therapy.
Main Methods:
- Systematic review of published clinical trials on proangiogenic therapies.
- Analysis of data from protein and gene therapy-based angiogenesis studies.
- Critical assessment of trial designs, outcomes, and limitations.
Main Results:
- Recent clinical trials have explored novel gene and protein-based proangiogenic strategies.
- Advancements in understanding endothelial cell activation and microvessel stabilization are noted.
- Analysis reveals recurring pitfalls in trial design and execution that impacted outcomes.
Conclusions:
- Proangiogenic therapies, particularly gene and protein-based approaches, hold therapeutic potential.
- Addressing identified pitfalls in clinical trial design is essential for future success.
- Continued research is needed to optimize angiogenesis therapy for clinical application.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...